Flanvotumab (IMC-20D7S) is a human monoclonal antibody targeting to tyrosinase-related protein (TYRP1), specifically expressed in melanocytes and melanoma cells. Flanvotumab acts function via natural killing-mediated antibody-dependent cell-mediated cytotoxicity (ADCC). Flanvotumab has potent anti-tumor activity and good tolerance[1].
Flanvotumab 是基于 TA99 而研制的，TA99 是一种小鼠 IgG2a 抗 TYRP1 单抗，定位于皮下黑色素瘤异种移植，并在临床前模型中抑制同基因肿瘤生长[1]。
TA99 的抗肿瘤作用依赖于完整的抗体、Fc 受体的存在和自然杀伤 (NK) 细胞[1]。
[1]. Khalil DN, et al. An Open-Label, Dose-Escalation Phase I Study of Anti-TYRP1 Monoclonal Antibody IMC-20D7S for Patients with Relapsed or Refractory Melanoma. Clin Cancer Res. 2016 Nov 1;22(21):5204-5210.